JP2016519685A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519685A5
JP2016519685A5 JP2016507671A JP2016507671A JP2016519685A5 JP 2016519685 A5 JP2016519685 A5 JP 2016519685A5 JP 2016507671 A JP2016507671 A JP 2016507671A JP 2016507671 A JP2016507671 A JP 2016507671A JP 2016519685 A5 JP2016519685 A5 JP 2016519685A5
Authority
JP
Japan
Prior art keywords
sulfonamide
fluorophenyl
fluoropropane
morpholinoquinazolin
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016507671A
Other languages
English (en)
Japanese (ja)
Other versions
JP6496301B2 (ja
JP2016519685A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/033727 external-priority patent/WO2014169167A1/en
Publication of JP2016519685A publication Critical patent/JP2016519685A/ja
Publication of JP2016519685A5 publication Critical patent/JP2016519685A5/ja
Application granted granted Critical
Publication of JP6496301B2 publication Critical patent/JP6496301B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016507671A 2013-04-12 2014-04-11 Ras/raf/mek/erk経路およびpi3k/akt/pten/mtor経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン Expired - Fee Related JP6496301B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811408P 2013-04-12 2013-04-12
US61/811,408 2013-04-12
PCT/US2014/033727 WO2014169167A1 (en) 2013-04-12 2014-04-11 Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways

Publications (3)

Publication Number Publication Date
JP2016519685A JP2016519685A (ja) 2016-07-07
JP2016519685A5 true JP2016519685A5 (OSRAM) 2017-06-01
JP6496301B2 JP6496301B2 (ja) 2019-04-03

Family

ID=50771612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507671A Expired - Fee Related JP6496301B2 (ja) 2013-04-12 2014-04-11 Ras/raf/mek/erk経路およびpi3k/akt/pten/mtor経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン

Country Status (13)

Country Link
US (5) US9499495B2 (OSRAM)
EP (1) EP2984088B1 (OSRAM)
JP (1) JP6496301B2 (OSRAM)
KR (1) KR20150143672A (OSRAM)
CN (1) CN105283454B (OSRAM)
AU (1) AU2014250836C1 (OSRAM)
BR (1) BR112015025901A8 (OSRAM)
CA (1) CA2909310A1 (OSRAM)
IL (2) IL242020B (OSRAM)
MX (1) MX2015014387A (OSRAM)
RU (1) RU2015148359A (OSRAM)
WO (1) WO2014169167A1 (OSRAM)
ZA (1) ZA201507750B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
CA3029875C (en) * 2016-07-06 2023-12-19 The Regents Of The University Of Michigan Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
CN108239075B (zh) * 2016-12-26 2021-07-02 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
EP4169918B8 (en) * 2016-12-26 2025-09-24 Institute of Materia Medica, Chinese Academy of Medical Sciences Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
CN108239074B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239076B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
WO2018212774A1 (en) * 2017-05-17 2018-11-22 Vanderbilt University Quinazoline compounds as modulators of ras signaling
IL271230B2 (en) 2017-06-21 2024-06-01 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2019014668A1 (en) * 2017-07-14 2019-01-17 Asana Biosciences, Llc FORMULATIONS, METHODS, KIT AND DOSAGE FORMS FOR ENHANCED STABILITY OF ACTIVE PHARMACEUTICAL INGREDIENT
CN108623582A (zh) * 2017-10-10 2018-10-09 河南省锐达医药科技有限公司 一类新型含取代基吡啶并嘧啶化合物的制备方法
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
CN111499634B (zh) * 2019-01-31 2023-05-12 贝达药业股份有限公司 一种喹唑啉化合物及其在医药上的应用
CN112341434B (zh) * 2019-08-08 2021-11-26 恩瑞生物医药科技(上海)有限公司 PI3K/mTOR蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
WO2021086957A1 (en) 2019-11-01 2021-05-06 Fmc Corporation An efficient new process for synthesis of 2-amino-5-chloro-n-,3-dimethylbenzamide
CR20220241A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
EP4247795A1 (en) * 2020-11-18 2023-09-27 Deciphera Pharmaceuticals, LLC Gcn2 and perk kinase inhibitors and methods of use thereof
EP4334325A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CN113416181B (zh) * 2021-08-02 2022-05-03 四川大学 喹唑啉类衍生物及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20250084078A1 (en) * 2022-01-04 2025-03-13 Genfleft Therapeutics (Shanghai) Inc. Fused ring-substituted six-membered heterocyclic compound, and preparation method therefor and use thereof
CN115894211A (zh) * 2022-11-10 2023-04-04 山东龙立恒医药有限公司 一种3-羟基-4-甲基苯甲酸的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
TW200801012A (en) * 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
WO2009039140A1 (en) 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
NZ617520A (en) * 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
EP2344490A2 (en) * 2008-10-03 2011-07-20 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines active on pi3k
CN102770426B (zh) * 2010-02-05 2016-03-23 诺瓦提斯公司 作为蛋白激酶抑制剂的化合物和组合物
CN102762565A (zh) * 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors

Similar Documents

Publication Publication Date Title
JP2016519685A5 (OSRAM)
RU2015148359A (ru) Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor
JP7169412B2 (ja) 抗癌活性及び抗増殖活性を呈する2-アミノピリミジン-6-オン及び類似体
US9133183B2 (en) Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
DK2858646T3 (en) DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS AS KINASE INHIBITORS IN TREATMENT OF PROLIFERATIVE DISEASES
ES2879474T3 (es) Compuestos y composiciones para modular las actividades de la quinasa mutante de EGFR
CA2729725C (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
JP2020503299A5 (OSRAM)
JP2019031560A5 (OSRAM)
JP2015529224A5 (OSRAM)
JP2017512786A5 (OSRAM)
RU2012132426A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ
JP2010524914A5 (OSRAM)
HRP20220990T1 (hr) 3-supstituirane propionske kiseline kao inhibitori alfa v integrina
EA034931B1 (ru) Индолкарбоксамидные соединения
RU2009144191A (ru) Имидазопиридиновые ингибиторы киназ
RU2012132278A (ru) Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
JP2016516026A5 (OSRAM)
JP2017526711A5 (OSRAM)
RU2016141647A (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ
ME02215B (me) Agensi koji induciraju apoptozu za liječenje raka te imunih i autoimunih bolesti
JP2016513660A5 (OSRAM)
JP2015524837A5 (OSRAM)
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака
CN109790158A (zh) 作为jak抑制剂杂环化合物,该化合物的盐类及其治疗用途